key: cord-0834585-6noowoya
authors: Pretti, Marco Antonio M.; Galvani, Rômulo G.; Scherer, Nicole M.; Farias, Alessandro S.; Boroni, Mariana
title: In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape
date: 2022-02-08
journal: Infect Genet Evol
DOI: 10.1016/j.meegid.2022.105236
sha: 0e3c5718998a49379dee209269b0d2d9732a1bbf
doc_id: 834585
cord_uid: 6noowoya

SARS-CoV-2 variants of concern have emerged since the COVID-19 outburst, notably the lineages detected in the UK, South Africa, and Brazil. Their increased transmissibility and higher viral load put them in the spotlight. Much has been investigated on the ability of those new variants to evade antibody recognition. However, little attention has been given to pre-existing and induced SARS-CoV-2-specific CD8+ T cell responses by new lineages. In this work, we predicted SARS-CoV-2-specific CD8+ T cell epitopes from the main variants of concern and their potential to trigger or hinder CD8+ T cell response by using HLA binding and TCR reactivity in silico predictions. Also, we estimated the population's coverage for different lineages, which accounts for the ability to present a set of peptides based on the most frequent HLA alleles of a given population. We considered binding predictions to 110 class I HLA alleles from 29 countries to investigate differences in the fraction of individuals expected to respond to a given epitope set from new and previous lineages. We observed a higher population coverage for the variant detected in the UK (B.1.1.7), and South Africa (B.1.351), as well as for the Brazilian P.1 lineage, but not P.2, compared to the reference lineage. Moreover, individual mutations such as Spike N501Y and Nucleocapsid D138Y were predicted to have an overall stronger affinity through HLA-I than the reference sequence while Spike E484K shows signs of evasion. In summary, we provided evidence for the existence of potentially immunogenic and conserved epitopes across new SARS-CoV-2 variants, but also mutant peptides exhibiting diminished or abolished HLA-I binding. It also highlights the augmented population coverage for three new lineages. Whether these changes imply more T cell reactivity or potential to evade from CD8+ T cell responses requires experimental verification.

reactivity in silico predictions. Also, we estimated the population's coverage for different lineages, which accounts for the ability to present a set of peptides based on the most frequent HLA alleles of a given population. We considered binding predictions to 110 class I HLA alleles from 29 countries to investigate differences in the fraction of individuals expected to respond to a given epitope set from new and previous lineages. We observed a higher population coverage for the variant detected in the UK (B.1.1.7), and South Africa (B.1.351), as well as for the Brazilian P.1 lineage, but not P.2, compared to the reference lineage. Moreover, individual mutations such as Spike N501Y and Nucleocapsid D138Y were predicted to have an overall stronger affinity through HLA-I than the reference sequence while Spike E484K shows signs of evasion. In summary, we provided evidence for the existence of potentially immunogenic and conserved epitopes across new SARS-CoV-2 variants, but also mutant peptides exhibiting diminished or abolished HLA-I binding. It also highlights the augmented population coverage for three new lineages. Whether these changes imply more T cell reactivity or potential to evade from CD8+ T cell responses requires experimental verification. 

Since the COVID-19 outburst, researchers are struggling in the entire world to better understand why the disease manifests in many different ways, generating a vast range of symptoms. During the last months, new SARS-CoV-2 lineages were detected in the United Kingdom, South Africa, and Brazil (CDC, 2020) . Some of these new mutations are of global interest since they seem to increase SARS-CoV-2 transmission (Ozono et al., 2021; Volz et al., 2021) . Most variants of concern have multiple mutations in the S and N gene (Hodcroft, 2021) which codes for immunodominant CD8+ T cell peptides (Grifoni et al., 2020; Schreibing et al., 2021; Tarke et al., 2021a) . The emergence of these new lineages raised concerns about the reinfection of convalescent individuals as well as the effectiveness of available vaccines. Indeed, mRNA vaccine-elicited antibodies showed a reduced plasma neutralizing activity against new lineages . Consistently, Brazilian P.1 lineage seems to escape from neutralizing antibodies generated against previously circulating variants of SARS-CoV-2 as well as inactivated virus SARS-CoV-2 vaccine-elicited antibodies (de Souza et al., 2021) .

Interestingly, although neutralizing antibody titers and memory B cell responses can be long-lived in some human coronavirus infections, many studies have evidenced the role of T cell response to SARS-CoV-2 (Braun et al., 2020; Sekine et al., 2020; Tarke et al., 2021a) . SARS-CoV-2-specific CD8+ T cells from individuals with milder COVID-19 have higher perforin and granzyme activity than convalescent ones, showing an increased CD8+ T effector phenotype during the acute mild disease (Sekine et al., 2020) . Of note, the cytotoxic activity is also increased in CD4+ T cells responding to SARS-CoV-2 (Meckiff et al., 2020) .

vaccine design and in silico analysis of SARS-CoV-2 proteins have detected candidate epitopes specific for protective CD4+ or CD8+ T and B responses with low risks of allergy or autoimmunity (Jain et al., 2021; Safavi et al., 2020; Singh et al., 2020; Tahir Ul Qamar et al., 2020) . In fact, approved vaccines induce T cell response in addition to the production of neutralizing antibodies for immunization against SARS-CoV-2 (Corbett et al., 2020; Sahin et al., 2020; Vogel et al., 2021) .

The quality and amplitude of adaptive immunity are highly dependent on the Human Leukocyte Antigen (HLA) complex-mediated presentation of epitopes to T cells. Previous works have already evidenced sets of SARS-CoV-2 peptides more likely to be presented through HLA molecules to CD8+ T cells (Barquera et al., 2020; Nguyen et al., 2020; Pretti et al., 2020) . In a recent study, our group adopted a computational approach to map populational coverage for SARS-CoV-2-derived peptides based on class I HLAs, which suggested a protective role of a higher S/N coverage ratio (Pretti et al., 2020) . Since most of the new SARS-CoV-2 variants are located in the proteins S and N, we decided to investigate whether mutations in these regions could modify peptide presentation, antigenic coverage, and impact T cell responses.

BetaCoV/Wuhan/IPBCAMS-WH-01/2019 genome assembly (GenBank:

MT019529.1) was downloaded and used as a wild-type reference (REF) sequence.

Non-synonymous Single-Nucleotide Variants (nsSNVs) and deletions in S and N genes of four SARS-CoV-2 upcoming variants of interest (VOI) (20I/501Y.V1, 20H/501Y.V2, 20J/501Y.V3, and 20B/S.484K) were retrieved from the online database covariants.org (Hodcroft, 2021) . A list of S and N mutations analyzed here can be found in Supplementary Table S1. 2.2 Binding and antigenicity predictions population. Binding predictions were performed as previously described (Pretti et al., 2020) and peptides classified as Strong (SB) and Weak Binders (WB) were used in the following analysis. In summary, netCTLpan1.1 (Stranzl et al., 2010) was used to obtain predictions for TAP transport and peptide cutting to accurately select the peptides more likely to be transported to the endoplasmic reticulum and cleaved.

Those items of information were combined with HLA class I binding predictions performed by netMHCpan4.1 (Reynisson et al., 2020) , which is more accurate since it has been trained with more HLA alleles. Importantly, residues from positions -10 to +10 in relation to the mutated amino acid (aa) were used to predict 8 to 11-mer binders. Only peptides that were distinct between each VOI and the REF were

considered in the analysis. Peptide antigenicity was predicted for all supported (102 out of 110) HLA alleles among the 110 using PRIME . The prediction was carried out with default parameters by providing a list of all binders predicted by netCTLpan (Stranzl et al., 2010) and filtering for TAP and cleavage scores as previously described (Pretti et al., 2020) . Peptides with scores equal to zero were excluded since they suggest no HLA presentation. were retrieved on 18/05/2021 and filtered for linear epitopes, MHC-I restricted, from SARS-CoV-2, positive assays, and from Human hosts. Besides this, studies with less than 50 assays were excluded and those remaining were curated to ensure that peptides were tested isolatedly and not pooled together. In addition, only experiments using either 'T cell CD8+' or 'PBMC' that tested S or N-derived epitopes were selected. Epitopes identified by binding predictions were excluded from the final dataset.

The analysis was conducted on the R environment v4.0, using the R packages Biostrings v2.56 for peptide sequence manipulation and alignment, ggmsa v0.0.5 for visualization, and ggpubr v0.3.0 for statistical analysis. Wilcoxon test was used for mean comparisons unless stated otherwise. A p-value < 0.05 was used as a threshold for mean comparisons except for the antigenicity score where a p<0.01 was used instead.

Focused on evaluating the class I HLA binding profile of peptides derived from some of the SARS-CoV-2 variants, 26 nsSNVs and two deletions located within the genes coding for proteins S and N were obtained (Hodcroft, 2021). The mutations represent the genetic variability within these two proteins of four VOI circulating worldwide (Supplementary Table S1 ). We have originated a set of 8 to 11-mer peptides from 21-length aa sequences comprising each variant, within a window of 10 residues before and after the variant whenever possible ( Figure S1 ). The distribution of HLA frequencies among countries used in this work can be observed in Figure S2 and Supplementary Table S2 .

We obtained 352 unique peptides, comprising 8 to 11-mer predicted to be Table S3 and Table S4 ). Figure S3 ).

of SARS-CoV-2 epitope-specific T cell responses (Schulien et al., 2021; Tarke et al., 2021b Tarke et al., , 2021a . We then accessed data from the literature (Ferretti et al., 2020; Kared et al., 2020; Saini et al., 2021; Schulien et al., 2021; Tarke et al., 2021a) Table S5 ).

Importantly, the VOI-derived peptides could not be inspected in this analysis as they

were not individually tested in vitro to this date, to the best of our knowledge (Tarke et al., 2021b) .

Since we were interested in investigating the antigenicity of SARS-CoV-2 variants, we compared T cell responses for REF and VOI-derived peptides using a predictor that considers TCR recognition of HLA-restricted epitopes Figure S4 ). In contrast, nsSNVs T205I and Y144del showed lower antigenicity scores. Considering all nsSNVs associated with each VOI, an increased antigenicity was observed for 20H/501Y.V2 (p-value < 0.0001) and 20J/501Y.V3 (pvalue <0.001) lineages ( Figure 2 ). We then associated those results with our previous binding predictions (Figure1, Figure S3 ) considering only peptides with significant differences between REF and VOI lineages. We classified the significant results by mutation and highlighted the general interest in them either for their potential association with immune evasion or being used for vaccine development ( 

Despite the differences in binding profile and antigenicity, the HLA allelespresenting SARS-CoV-2 binder peptides are not necessarily equally distributed across different countries. Therefore, we investigated how different populations are predicted to be covered for the four VOI compared to the REF lineage using HLA frequency data from the 29 countries. In this specific analysis, we considered the allele frequencies of the class I HLA alleles in each analyzed population and the number of S and N-derived peptides (epitope hits) they are likely to present ( Figure   3 ). We observed a significant difference ( Together, these findings indicate a remarkable increment in antigen coverage for three new lineages, increased HLA-I presentation for the majority of the analyzed nsSNVs as well as increased antigenicity scores for 20H/501Y.V2 and 20J/501Y.V3.

However, in vitro and in vivo approaches are needed to validate these findings.

The outburst of new SARS-CoV-2 variants capable of faster spreading than previous lineages is a major concern for health systems worldwide. Four of them bear nsSNV that confer more transmissibility than other circulating coronaviruses (Ozono et al., 2021; Volz et al., 2021) On the other hand, 501Y substitution has a stronger affinity to the HLA alleles than the REF peptides but, similarly to E484K, are able to escape from antibody recognition (Baum et al., 2020; . Accordingly, N501Y and D138Y

substitutions showed increased HLA affinities and may be good targets to trigger CD8+ T cell responses. In addition, our previous work suggested that HLA presentation of N-derived peptides, rather than S-derived ones, was associated with high mortality rates (Pretti et al., 2020) . Based on that, the fact that the B.1.1.7, B.1.351, and P.1 Lineage potentially present more N-derived epitopes than the original lineage could be a major concern to the protective response in convalescent and vaccinated individuals. In fact, all nsSNVs on the protein N, e.g. D3L, P80R, S235F, and T205I, generated more potential epitopes in comparison to the REF Class-I binding and immunogenicity for CD8+ T cell response previously described by Schreibing and collaborators (Schreibing et al., 2021) . While changes in this specific region leading to reduced or lack of affinities may culminate in the escape of the virus from the protective response of T cells, either in convalescent or vaccinated individuals, enhanced affinities could favor a more intense response.

When validating our results by comparing the predictions with publicly available in vitro data from the IEDB, we noticed that the overlap of peptide:HLA pairs was higher when considering the most frequent alleles. This is expected since in vitro testing does not usually consider less frequent HLAs. Although in silico analyses are able to estimate the binding affinities for less frequent alleles, they are usually less accurate. Moreover, since many epitopes known to trigger T cell responses by in vitro studies are lost in the new lineages, this could contribute to impair the recognition of The overall susceptibility to new SARS-CoV-2 lineages is a major concern. We have used a populational coverage strategy to investigate whether the predicted ability of a broad population to recognize and present the viral epitopes is impacted 

Overall 

The sequence of SARS-CoV-2 can be found at the GenBank with the ID:

MT019529.1. The list of HLA-I alleles is available in a previous publication (Pretti et al., 2020) . All software used in this work is free for academic use.

The following are the supplementary data related to this article.

SupplementaryTable S1. List of SARS-CoV-2 nsSNV used in the analysis. predictors. Binder peptides were selected according to netMHCpan notation of strong (%Rank < 0.5) and weak binder (%Rank < 2.0) peptides; non-binder peptides were excluded.The number of HLA alleles presenting at least 1 binder is depicted for VOI (Red) and REF (Black) peptides. The nsSNV N:S235F did not generate any binder (Supplementary Table S2 and Supplementary Table S1 ). 

• Most SARS-CoV-2 snSNV located in Spike and Nucleosome are predicted to increase T-cell reactivity.

• The Spike mutation E484K is potentially associated with T-cell evasion.

• Populational approaches to predict T-cell reactivity to new SARS-CoV-2 lineages could help understanding the susceptibility to specific lineages. 

Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide

Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

Persistent cellular immunity to SARS-CoV-2 infection

Predicting population coverage of T-cell epitope-based diagnostics and vaccines

Emerging SARS-CoV-2 Variants | CDC [WWW Document

Most viral peptides displayed by class I MHC on infected cells are immunogenic

Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination

Antibody evasion by the P.1 strain of SARS-CoV-2

Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein

Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape

Imbalance of Regulatory and Cytotoxic SARS-CoV-2-Reactive CD4+ T Cells in COVID-19

Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2

SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity

HLA class I alleles are associated with peptide-binding repertoires of different size, affinity, and immunogenicity

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

2020. Class I HLA Allele Predicted Restricted Antigenic Coverages for Spike and Nucleocapsid Proteins Are Associated With Deaths Related to COVID-19. Front

Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches

BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans

SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients

Prediction of neo-epitope immunogenicity reveals TCR recognition determinants and provides insight into immunoediting

Dissecting CD8+ T cell pathology of severe SARS-CoV-2 infection by single-cell epitope mapping

Characterization of pre-existing and induced SARS-CoV-2-specific CD8+ T cells

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19

Designing a multi-epitope peptide based vaccine against SARS-CoV-2

NetCTLpan: panspecific MHC class I pathway epitope predictions

Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2

Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases

Negligible impact of SARS-CoV-2 variants on CD4 + and CD8 + T cell reactivity in COVID-19 exposed donors and vaccinees

Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK

UniProt: the universal protein knowledgebase in 2021

BNT162b vaccines protect rhesus macaques from SARS-CoV-2

Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

The authors would like to thank the Bioinformatics Core Facility (INCA-RJ) for their support.

The authors declare that they have no competing interests.

 Supplementary Table S2 . Distribution of HLA allelic frequency in the 39 analyzed